Us Bancorp \De\ Intellia Therapeutics, Inc. Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

A detailed history of Us Bancorp \De\ transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 755 shares of NTLA stock, worth $11,166. This represents 0.0% of its overall portfolio holdings.

Number of Shares

755

Previous 895 15.64%

Holding current value

$11,166

Previous $20,000 25.0%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$19.72 - $27.36 $2,760 - $3,830	-140 Reduced 15.64%	755 $15,000
Q2 2024 Aug 06, 2024	SELL	$20.02 - $27.22 $127,547 - $173,418	-6,371 Reduced 87.68%	895 $20,000
Q1 2024 May 07, 2024	SELL	$23.82 - $32.8 $38,350 - $52,807	-1,610 Reduced 18.14%	7,266 $199,000
Q4 2023 Feb 09, 2024	BUY	$23.16 - $32.34 $50,697 - $70,792	2,189 Added 32.74%	8,876 $270,000
Q3 2023 Nov 03, 2023	SELL	$31.62 - $45.78 $6,703 - $9,705	-212 Reduced 3.07%	6,687 $211,000
Q2 2023 Aug 09, 2023	SELL	$34.58 - $46.03 $5,221 - $6,950	-151 Reduced 2.14%	6,899 $281,000
Q1 2023 May 09, 2023	BUY	$33.3 - $44.82 $19,480 - $26,219	585 Added 9.05%	7,050 $262,000
Q4 2022 Feb 13, 2023	SELL	$33.21 - $62.69 $185,145 - $349,496	-5,575 Reduced 46.3%	6,465 $225,000
Q3 2022 Oct 27, 2022	BUY	$53.92 - $71.7 $180,362 - $239,836	3,345 Added 38.47%	12,040 $673,000
Q2 2022 Aug 01, 2022	SELL	$38.49 - $76.21 $250,492 - $495,974	-6,508 Reduced 42.81%	8,695 $449,000
Q1 2022 May 11, 2022	BUY	$58.27 - $118.99 $32,514 - $66,396	558 Added 3.81%	15,203 $1.1 Million
Q4 2021 Feb 11, 2022	BUY	$100.76 - $138.36 $181,368 - $249,048	1,800 Added 14.01%	14,645 $1.73 Million
Q3 2021 Nov 10, 2021	BUY	$132.37 - $176.78 $191,142 - $255,270	1,444 Added 12.67%	12,845 $1.72 Million
Q2 2021 Aug 05, 2021	BUY	$60.88 - $161.91 $327,230 - $870,266	5,375 Added 89.2%	11,401 $1.85 Million
Q1 2021 Apr 28, 2021	BUY	$46.59 - $83.68 $249,303 - $447,771	5,351 Added 792.74%	6,026 $484,000
Q4 2020 Feb 04, 2021	SELL	$18.83 - $63.53 $43,308 - $146,119	-2,300 Reduced 77.31%	675 $37,000
Q3 2020 Nov 10, 2020	SELL	$17.47 - $24.93 $43,675 - $62,325	-2,500 Reduced 45.66%	2,975 $59,000
Q2 2020 Aug 07, 2020	BUY	$11.14 - $22.87 $22,280 - $45,740	2,000 Added 57.55%	5,475 $115,000
Q1 2020 May 13, 2020	BUY	$9.44 - $15.58 $31,152 - $51,414	3,300 Added 1885.71%	3,475 $42,000
Q3 2018 Nov 01, 2018	BUY	$25.78 - $32.6 $4,511 - $5,705	175 New	175 $5,000

Others Institutions Holding NTLA

# of Institutions

315

Shares Held

91.5M

Call Options Held

442K

Put Options Held

880K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.12B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account